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Abstract. 
 
The membrane transport factor p115 func-
tions in the secretory pathway of mammalian cells. Us-
ing biochemical and morphological approaches, we 
show that p115 participates in the assembly and mainte-
nance of normal Golgi structure and is required for ER 
to Golgi trafﬁc at a pre-Golgi stage. Injection of anti-
bodies against p115 into intact WIF-B cells caused 
Golgi disruption and inhibited Golgi complex reassem-
bly after BFA treatment and wash-out. Addition of 
anti–p115 antibodies or depletion of p115 from a 
VSVtsO45 based semi-intact cell transport assay inhib-
ited transport. The inhibition occurred after VSV glyco-
protein (VSV-G) exit from the ER but before its deliv-
ery to the Golgi complex, and resulted in VSV-G 
protein accumulating in peripheral vesicular tubular 
clusters (VTCs). The p115-requiring step of transport 
followed the rab1-requiring step and preceded the 
 
Ca
 
2
 
1
 
-requiring step. Unexpectedly, mannosidase I re-
distributed from the Golgi complex to colocalize with 
VSV-G protein arrested in pre-Golgi VTCs by p115 de-
pletion. Redistribution of mannosidase I was also ob-
served in cells incubated at 15
 
8
 
C. Our data show that 
p115 is essential for the translocation of pre-Golgi 
VTCs from peripheral sites to the Golgi stack. This de-
ﬁnes a previously uncharacterized function for p115 at 
the VTC stage of ER to Golgi trafﬁc.
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NDOPLASMIC
 
 reticulum (ER) to Golgi traffic has
been extensively studied and a general framework
for the process has been elucidated (for reviews
see Bannykh et al., 1998; Hong, 1998; Glick and Malhotra,
1998). Export from the ER defines the first step of the
pathway and is mediated by the recruitment of the coat
protein (COP)
 
1
 
 II coats (composed of sec23/24 and sec13/
31 complexes and Sar1p) and the subsequent budding of
COP II–coated vesicles (for review see Barlowe, 1998).
The coat proteins direct the sorting and concentration of
proteins into the budding profiles, resulting in the prefer-
ential recruitment of cargo and exclusion of resident ER
proteins (Aridor et al., 1998). COP II vesicles bud from
specialized ER export sites morphologically defined as
an assembly of centrally located tubules surrounded by
budding profiles still attached to the ER (Bannykh et al.,
1996; Bannykh and Balch, 1997). Budded COP II vesicles
fuse with each other and with already fused vesicles to
form the polymorphic tubular structures that have been
called ERGIC (ER–Golgi intermediate compartment),
intermediate compartment, or vesicular tubular clusters
(VTCs) (Saraste and Svensson, 1991; Balch et al., 1994;
Tang et al., 1995; Bannykh et al., 1998). VTCs comprise a
morphologically and functionally complex compartment
integrating the anterograde ER to Golgi complex and the
retrograde recycling transport pathways. VTCs progress
from the cell periphery towards the microtubule organiz-
ing center and the adjoining Golgi complex on microtu-
bules in a dynein/dynactin–mediated process (for review
see Lippincott-Schwartz, 1998). During their limited life
span, VTCs undergo maturation by the selective recycling
and acquisition of specific proteins and the sequential ex-
change of specific molecules (e.g., COP II coats exchange
for COP I coats on VTCs [Pepperkok et al., 1993; Peter
et al., 1993; Aridor et al., 1995; Scales et al., 1997]). Cur-
rent evidence favors the view that COP I vesicles mediate
the selective retrieval of proteins from the Golgi back to
the VTCs and/or the ER, but their participation in antero-
grade traffic has not been ruled out (Lowe and Kreis,
1998). VTCs accumulate in the peri-Golgi region and,
once there, seem to form a more extensive array of tu-
bules, sometimes called the cis-Golgi network or the
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CGN. The exact relationship between VTCs and the CGN
is unclear and it is possible that VTCs fuse to make a CGN
or that the CGN is a large aggregate of individual VTCs.
Fusion of COP II vesicles to form VTCs and the subse-
quent assembly of VTCs to form cis-Golgi requires the
concerted function of numerous molecules, among them
the compartment-specific GTPases rab1 (Plutner et al.,
1991; Tisdale et al., 1992; Pind et al., 1994) and rab2
(Chavrier et al., 1990; Tisdale et al., 1992; Tisdale and
Balch, 1996), the general soluble fusion factors NSF
(
 
N
 
-ethylmaleimide–sensitive fusion factor) and SNAP
(soluble NSF attachment protein), and a set of distinct in-
tegral membrane proteins v-SNARES and t-SNARES
(vesicle- and target-SNAP receptors) believed to confer
specificity to fusion (Söllner et al., 1993; for reviews see
Rothman, 1994; Hay and Scheller, 1997; Nichols and Pel-
ham, 1998). The molecular mechanism underlying mem-
brane traffic is highly conserved, and in yeast, ER to Golgi
transport is also dependent on the function of the
compartment-specific GTPase Ypt1p (Segev et al., 1988),
the general fusion factors Sec18p (NSF homologue) and
Sec17p (SNAP homologue), and the specific interactions
of ER–Golgi SNAREs (Bos1p, Bet1p, Sed5p, Sec22p, and
Ykt6p) (for reviews see Ferro-Novick and Jahn, 1994; Mc-
New et al., 1997). SNAREs mediate membrane interac-
tions at relatively short distances (an assembled SNARE
pair has been shown to be only 14 nm; Hanson et al.,
1997), and it appears that donor and target membranes in-
teract at longer distances through the selective interac-
tions of specific tethering proteins (Orci et al., 1998; for re-
view see Pfeffer, 1996). In yeast, tethering of COP II
vesicles to Golgi membranes (yeast do not have morpho-
logically identifiable VTCs) occurs before SNARE com-
plex formation and is dependent on the function of a pe-
ripheral membrane–associated protein, Uso1p (Nakajima
et al., 1991; Sapperstein et al., 1996; Cao et al., 1998).
A mammalian homologue of Uso1p, p115, has been
characterized and shown to have a multidomain structure
composed of an NH
 
2
 
-terminal globular head, central
coiled-coil region, and a COOH-terminal acidic domain
(Barroso et al., 1995; Sapperstein et al., 1995; Yamakawa
et al., 1996). Like Uso1p, p115 assembles into parallel
dimers. Functionally, p115 has been identified as a re-
quirement in in vivo–reconstituted assays measuring cis- to
medial-Golgi transport (Waters et al., 1992), transcytotic
traffic (Barroso et al., 1995), regrowth of Golgi cisterna
from mitotic Golgi fragments (Rabouille et al., 1995, 1998;
Nakamura et al., 1997), and cisternal stacking (Shorter and
Warren, 1999). Consistent with the role of p115 in Golgi
events, p115 has been localized predominantly to the
Golgi at the light microscope level. However, by electron
microscopy, p115 was found preferentially associated with
VTCs adjacent to the Golgi stack (the close proximity of
VTCs to the Golgi [Ladinsky et al., 1999] makes them dif-
ficult to resolve from Golgi elements by immunofluores-
cence), and to cycle extensively between the Golgi and
earlier compartments of the secretory pathway (Nelson et
al., 1998). Such localization and cycling behavior is charac-
teristic for proteins involved in ER to Golgi traffic, sug-
gesting that p115, like Uso1p, might participate in this
stage of the secretory pathway.
Here, we show that p115 is critical for the dynamic
 
maintenance and the de novo assembly of morphologically
normal Golgi complexes, and that p115 is required for ER
to Golgi traffic at a pre-Golgi VTC stage, after the rab1-
requiring step but preceding the Ca
 
2
 
1
 
-requiring step. Bio-
chemical and morphological analysis of cargo VSV glyco-
protein (VSV-G) protein progression from the ER to the
Golgi indicated that p115 function is not essential for
events leading to the formation of VTCs, but that p115 is
required for the subsequent delivery of VTCs from the pe-
ripheral sites, where they form, to the Golgi stack. Charac-
terization of the p115-arrested VTCs showed that the cis-
Golgi enzyme mannosidase I (Mann I), but not Mann II,
specifically redistributed from the Golgi stack and colocal-
ized with such VTCs. Our results indicate that p115 is re-
quired for traffic progression along the secretory pathway
at a pre-Golgi VTC step, suggesting that p115 is essential
for events leading to VTC delivery to the Golgi stack.
 
Materials and Methods
 
Antibodies
 
Rabbit polyclonal antibodies against p115 were generated by immuniza-
tion with purified rat p115 (Barroso et al., 1995). For affinity purification
of antibodies, purified GST-p115 fusion protein was run on 7.5% acryl-
amide gels, and transferred to nitrocellulose. Strips of nitrocellulose con-
taining p115 were incubated with immune serum in PBS, 5% dried milk,
and 0.1% Tween 20 for 3 h at room temperature. Bound antibodies were
eluted with 0.1 M glycine, pH 3.0, and then neutralized with 1/10 vol 1 M
phosphate buffer, pH 7.4. These anti–p115 antibodies were either used in
transport assays or cross-linked to protein A–Sepharose 4 FF (Pharmacia
Biotech, Inc.) with dimethyl pimelimidate (Pierce Chemical Co.) accord-
ing to the manufacturer’s protocol, and subsequently used for p115 immu-
nodepletion experiments. Mouse polyclonal antibodies against GM130
were generated by immunization with inclusion bodies from bacteria ex-
pressing full-length GM130 (Nelson et al., 1998). Anti-giantin monoclonal
G1/133 (Linstedt and Hauri, 1993) and anti–ERGIC-53 monoclonal G1/93
(Schweizer et al., 1988) were provided by Dr. Hans-Peter Hauri (Univer-
sity of Basel, Basel, Switzerland). Polyclonal antibodies against Mann II
were kindly provided by Dr. Marilyn Farquhar (University of California,
San Diego, CA). mAbs against Mann II were from Sigma Chemical Co.
Anti–rab1 antibodies were a gift of Dr. Mark McNiven (Mayo Founda-
tion, Rochester, MN). Polyclonal antibodies against Mann I were pro-
vided by Dr. Kelley Moreman (University of Georgia, Athens, GA).
Monoclonal anti–VSV-G protein (P5D4) was provided by Dr. Kathryn
Howell (University of Colorado, Denver, CO). Goat anti–rat and anti–
mouse antibodies conjugated with FITC or rhodamine were purchased
from Jackson ImmunoResearch.
 
Generation of GST-p115 Construct
 
Full-length p115 was cloned into the BamHI-NotI restriction sites of the
pGEX-6P-2 GST vector (Pharmacia Biotech, Inc.). p115 was obtained by
PCR using as a template a pBluescript-II-KS plasmid (Stratagene) encod-
ing rat p115 cDNA previously described (Barroso et al., 1995). GST-p115
fusion protein expression and purification were performed according to
the manufacturer’s protocol.
 
Purification of Cytosolic p115
 
p115 was affinity-purified from rat liver cytosol using affinity-purified
polyclonal antibodies raised against p115 cross-linked to beads as previ-
ously described (Barroso et al., 1995). The p115 preparation was judged
homogenous by Coomassie blue staining.
 
Microinjection
 
Ascites raised against p115 (3A10) were concentrated by centrifugation in
a Microcon 30 (Pierce Chemical Co.) and dialyzed into MI buffer (48 mM
K
 
2
 
HPO
 
4
 
, 140 mM NaH
 
2
 
PO
 
4
 
, 4.5 mM KH
 
2
 
PO
 
4
 
, pH 7.2). Denaturation was
by boiling to 100
 
8
 
C for 3 min. Before injection, solutions were centrifuged 
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at 15,800 
 
g
 
 for 20 min, and then mixed with 1/10 vol of Texas red–dextran
(TR-dextran, 10,000 D, 50 mg/ml) and 10
 
3
 
 MI buffer. Injections into the
cytoplasm of WIF-B cells were performed with an Eppendorf transjector
5246 and micromanipulator 5171 attached to a Zeiss Axiovert 100 micro-
scope. The pressure was 50 hectoPascal for 0.1–0.2 s using an Eppendorf
femtotip needle. After injection, cells were incubated with Ham’s F12 me-
dium (Gibco Laboratories) at 37
 
8
 
C for 2–3 h, fixed, and processed for im-
munofluorescence. In some experiments, 2.5 
 
m
 
g/ml BFA was used. Flu-
orescent images were collected with the MCID analysis system (Zeiss
Axiovert 100 microscope) or with a Zeiss confocal microscope (LSM410).
Digitized images were cropped, assembled, and labeled in Adobe Photo-
shop.
 
Semi-intact Cell ER–Golgi Transport Assay
 
The ER to Golgi transport assay was performed as described previously
(Beckers et al., 1987; Schwaninger et al., 1992b). In brief, normal rat kidney
(NRK) cells, or LEC-1 (a CHO-derived cell line deficient in NAGT-1 and
analogous to CHO15B) cells were grown on 10-cm petri dishes to 80–90%
of confluence and infected with the temperature-sensitive strain of the ve-
sicular stomatitis virus, VSVtsO45 at 32
 
8
 
C for 3–4 h (Bergmann, 1989).
The cells were pulse-labeled with 
 
35
 
S-trans label (200 mCi/ml; ICN) at the
restrictive temperature (42
 
8
 
C) for 10 min, chased with complete medium
for 5 min, and perforated by hypotonic swelling and scraping to make
semi-intact cells. A transport reaction was performed in a final total vol-
ume of 40 
 
m
 
l in a buffer that contained 25 mM Hepes-KOH, pH 7.2, 75 mM
potassium acetate, 2.5 mM magnesium acetate, 5 mM EGTA, 1.8 mM
CaCl
 
2
 
, 1 mM 
 
N
 
-acetylglucosamine, ATP regeneration system (1 mM ATP,
5 mM creatine phosphate, and 0.2 IU rabbit muscle creatine phosphoki-
nase), 5 
 
m
 
l rat liver cytosol, 5 
 
m
 
l of semi-intact cells in 50 mM Hepes-
KOH, pH 7.2, and 90 mM potassium acetate. Transport was initiated by
transfer of cells to 32
 
8
 
C. After 90 min of incubation, cells were pelleted,
resuspended in appropriated buffer, and digested with endoglycosidase
H (endo-H) or endoglycosidase D (endo-D) as described previously
(Schwaninger et al., 1992b). The samples were analyzed on 8% SDS-
PAGE and fluorography. The transport was quantified using GS-700 imag-
ing densitometer (Bio-Rad Laboratories). For antibody inhibition of trans-
port assay, affinity-purified p115 antibodies were added into the complete
assay cocktail and incubated on ice for 30 min before use. Staging experi-
ments were performed as previously described (Peter et al., 1998).
 
Immunodepletion of Rat Liver Cytosol
 
Rat liver cytosol was prepared as previously described (Dascher et al.,
1994). Immunopurified anti–p115 antibodies cross-linked to protein
A–Sepharose were incubated (2 h at 4
 
8
 
C) with rat liver cytosol, and the
level of p115 depletion was tested by SDS-PAGE and immunoblotting.
 
Morphological Analysis of VSVtsO45
G Protein Transport
 
This analysis was performed as described previously (Plutner et al., 1992).
In brief, NRK cells plated on coverslips were infected with VSVtsO45 at
32
 
8
 
C for 30 min, followed by an incubation at 42
 
8
 
C for 3 h, and then
shifted to ice and permeabilized with digitonin (20 mg/ml). Coverslips
were incubated in various transport cocktails at 32
 
8
 
C for 90 min. For anti-
body inhibition of the transport assay, affinity-purified p115 antibodies
were added into the complete transport mix and incubated on ice for 30
min followed by an incubation at 32
 
8
 
C for 90 min. Transport was deter-
mined by transferring coverslips to ice and fixing them in 3% formalde-
hyde/PBS for 10 min. The coverslips were processed for double label im-
munofluorescence.
 
Immunofluorescence Microscopy
 
Cells grown on glass coverslips were washed three times in PBS and fixed
in 3% paraformaldehyde in PBS for 10 min at room temperature.
Paraformaldehyde was quenched with 10 mM ammonium chloride, and
cells were permeabilized with PBS, 0.1% Triton X-100 for 7 min at room
temperature. The coverslips were washed (three times, 2 min per wash)
with PBS, and blocked in PBS, 0.4% fish skin gelatin, 0.2% Tween 20 for 5
min, followed by blocking in PBS, 2.5% goat serum, 0.2% Tween for 5
min. Cells were incubated with primary antibody diluted in PBS, 0.4% fish
skin gelatin, and 0.2% Tween 20 for 45 min at 37
 
8
 
C. Coverslips were
washed (five times, 5 min per wash) with PBS and 0.2% Tween 20. Sec-
ondary antibodies coupled to FITC or rhodamine were diluted in 2.5%
goat serum and incubated on coverslips for 30 min at 37
 
8
 
C. Coverslips
were washed with PBS and 0.2% Tween 20 as above, and mounted on
slides in 9:1 glycerol/PBS with 0.1% q-phenylenediamine. Fluorescence
patterns were visualized with an Olympus IX70 epifluorescence micro-
scope. Optical sections were captured with a CCD high resolution camera
equipped with a camera/computer interface. Images were analyzed with a
power Mac 9500/132 computer using IPLab Spectrum software (Scanalyt-
ics Inc.).
 
Results
 
Antibodies against p115 Disrupt Golgi Structure and 
Prevent Reassembly of Golgi Stacks In Vivo
 
The requirement for p115 has been previously studied
only in in vitro–reconstituted assays (Waters et al., 1992;
Barroso et al., 1995; Rabouille et al., 1995, 1998). To exam-
ine the function of p115 in vivo, monoclonal anti–p115 an-
Figure 1. Antibodies against p115 cause Golgi complex disas-
sembly. mAbs against p115 mixed with TR-dextran (A–C), or
mAbs against 59-nucleotidase mixed with TR-dextran (D–F)
were microinjected into the cytoplasm of WIF-B cells. Phase im-
ages of cells are shown (A and D). Injected cells are identified by
TR-dextran (B and E) and are traced in outline in C and F. Cells
were fixed 2 h after injection and processed for immunofluores-
cence using antibodies against Mann II (C and F). Cells injected
with anti–p115 antibodies, but not uninjected cells or cells in-
jected with control antibodies show disassembly of Golgi com-
plexes. Bar, 10 mm. 
The Journal of Cell Biology, Volume 147, 1999 1208
 
tibodies were microinjected into WIF-B cells (Shanks et al.,
1994), and their effect on Golgi structure was monitored
by the distribution of Mann II. As shown in Fig. 1, injec-
tion of anti–p115 antibodies had an effect on Golgi struc-
ture. A field of cells is shown by phase-contrast (A), and
the injected cells are identified by their content of coin-
jected TR-dextran (B). Within 2 h after injection, the
Golgi complexes in all injected cells were disassembled,
and Mann II was present in relatively large punctate struc-
tures dispersed throughout the cells (C). The structures
appeared superficially similar to those observed in cells
transfected with mutant forms of p115 lacking portions of
the globular head or the coiled-coil tail (Nelson et al.,
1998). Injection of control antibodies against the bile
canalicular plasma membrane protein 5
 
9
 
-nucleotidase did
not perturb Golgi structure (D–F).
ER to Golgi traffic can be disrupted by brefeldin A
(BFA), which inhibits a guanine nucleotide exchange fac-
tor for ADP ribosylation factor; thus, preventing assembly
of COP I coats, and ultimately blocking normal traffic be-
tween ER and the Golgi (Donaldson et al., 1992b; Helms
and Rothman, 1992). This results in COP I–independent
tubulation of the Golgi and the relocation of Golgi
proteins into the ER (Misumi et al., 1986; Fujiwara et
al., 1988; Lippincott-Schwartz et al., 1989). BFA-induced
membrane redistribution has given valuable insights into
components and mechanisms involved in regulation of the
secretory pathway (Klausner et al., 1992), and we com-
bined BFA treatments with microinjection of anti–p115
antibodies to characterize the effect of anti–p115 antibod-
ies on ER–Golgi traffic.
The redistribution of Mann II from the Golgi into the ER
in control WIF-B cells or in cells injected with anti–p115
antibodies was examined first. As shown in Fig. 2, Mann II
was detected in a normal perinuclear Golgi pattern in un-
injected cells or in injected cells immediately after the an-
tibody injection and before BFA treatment (A). The in-
jected cells were identified by the presence of anti–p115
IgG (B). When an analogous field of cells was treated with
BFA for 30 min, Mann II relocated from the Golgi to the
ER in uninjected and injected cells (C). Only a single time
point was analyzed, and it remains possible that the kinet-
ics of Mann II redistribution may have varied in injected
and uninjected cells. Some Golgi staining was still evident
in uninjected and injected cells after the BFA treatment
(C, arrowheads). After 30 min, the majority of anti–p115
IgG was associated with membranes, presumably repre-
senting p115 localization (D), as shown previously (Nelson
et al., 1998). The results suggest that anti–p115 antibodies
do not block the Golgi to ER redistribution of Mann II in-
duced by BFA treatment.
To examine if the antibodies inhibit the movement of
Mann II from the ER, WIF-B cells were first treated with
BFA for 30 min to relocate Mann II from the Golgi to the
ER, and then injected with anti–p115 antibodies. The tem-
poral sequence of Golgi recovery after BFA wash-out was
followed. As shown in Fig. 3 A, punctate structures dis-
persed throughout the cell were detected after a 10-min
BFA wash-out in both, uninjected and injected cells. The
size and distribution of the elements were comparable,
suggesting that the antibodies do not block early stages of
BFA recovery. A difference was seen after 30 min of BFA
wash-out, when defined Golgi structures could be seen in
uninjected cells (C, arrows), while significantly smaller,
dispersed structures were present in the injected cells (C,
arrowheads). The effect was also evident after 120 min of
BFA wash-out, when compact Golgi structures were seen
in uninjected cells (E, arrows), whereas dispersed punctate
structures persisted in the injected cells (E, arrowheads).
In some injected cells, a more Golgi-like Mann II pattern
was seen (E, asterisk), but the structure appeared less
compact and organized. These results suggest that anti–
p115 antibodies prevent the reassembly of normal Golgi
complexes.
 
p115 Is Associated with Functional VTCs Moving
VSV-G Protein from the ER to the Golgi
 
The inhibitory effects of anti–p115 antibodies on the main-
tenance and reassembly of normal Golgi structure, cou-
pled with the previous finding that p115 is present on
VTCs and cycles between the Golgi and earlier secretory
compartments (Nelson et al., 1998), suggested a potential
role for p115 in ER to Golgi transport. To analyze if p115
is present on functional VTCs transporting cargo from the
ER to the Golgi, we used a temperature-sensitive strain of
the vesicular stomatitis virus (VSVtsO45) as a transport
marker (for review see Bergmann, 1989). The viral VSV-G
protein fails to exit the ER at 42
 
8
 
C, the nonpermissive
temperature, but after shifting the cells to the permissive
temperature of 32
 
8
 
C, a wave of VSV-G protein enters the
Figure 2. Antibodies against p115 do not block BFA-induced
retrograde Golgi to ER traffic. Mouse mAbs against p115 were
microinjected into the cytoplasm of WIF-B cells. Cells were fixed
immediately after injection (A and B) or after a 30-min BFA
treatment (C and D). Cell were processed for double label immu-
nofluorescence using antibodies against Mann II (A and C) or
against mouse IgG (B and D). Relocation of Mann II from the
Golgi to the ER appears indistinguishable in injected and unin-
jected cells. Golgi remnants were detected in some cells after the
30-min BFA treatment (C, arrowheads). 
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secretory pathway, and its movement from the ER to the
Golgi can be monitored morphologically (Pepperkok et al.,
1993; Balch et al., 1994). NRK cells infected with the virus
and cultured at the nonpermissive temperature for 3 h con-
tain VSV-G protein in the ER, whereas p115 is predomi-
nantly detected in the Golgi region (Fig. 4, A–C). When
infected cells were subsequently shifted from 42 to 15
 
8
 
C
and incubated at 15
 
8
 
C for 3 h, VSV-G protein movement
to the Golgi was arrested in peripheral VTCs that also
contained p115 (Fig. 4, D–F). We have shown previously
that p115 colocalizes with the VTC marker, ERGIC-53
(Schweizer et al., 1988) when VTCs are preferentially ac-
cumulated during low (15
 
8
 
C) temperature incubation (Sa-
raste and Svensson, 1991; Nelson et al., 1998). Bonafide
Golgi proteins such as galactosyl-transferase or Mann II
do not redistribute to peripheral VTCs after low tempera-
ture treatment (Lippincott-Schwartz et al., 1990; Nelson
et al., 1998; see Fig. 10 E). When infected cells were shifted
from 42 to 32
 
8
 
C for 1 h, VSV-G protein and p115 colocal-
ized in the Golgi (Fig. 4, G–I). These results indicate that
p115 is a component of VTCs that move VSV-G protein
from the ER to the Golgi, and raise the possibility that
p115 could be involved in VTC dynamics.
 
p115 Is Required for ER to Golgi Transport
 
Although p115 has been identified as a cis- to medial-
Golgi transport factor (Waters et al., 1992), its yeast ho-
mologue, Uso1p, has been shown to act in ER to Golgi
traffic (Nakajima et al., 1991; Cao et al., 1998). To examine
directly p115 participation in ER to Golgi traffic, we used
a previously developed semi-intact cell transport assay
(Beckers et al., 1987). NRK cells were infected with
VSVtsO45 and radiolabeled at 42
 
8
 
C. Cells were permeabi-
 
lized to remove endogenous cytosol, supplemented with
exogenous transport cocktails, and shifted to 32
 
8
 
C to ini-
tiate VSV-G protein transport. Delivery of VSV-G pro-
tein to the Golgi was assessed by its carbohydrate process-
ing, as defined by endo-H resistance. VSV-G protein
oligosaccharide chains are processed during transport by
the sequential actions of enzymes localized throughout the
Golgi stack. The processing involves the sequential func-
tion of Mann I and 
 
N
 
-acetylglucosamine transferase I
(NAGT-1), both considered cis-Golgi enzymes (Schwan-
inger et al., 1992b), and of Mann II, localized in the medial/
trans Golgi stack (Velasco et al., 1993). After processing
by Mann I, VSV-G acquires endo-D sensitivity, whereas
subsequent processing by NAGT-1 and Mann II confers
endo-H resistance. As shown in Fig. 5 A, when complete
transport cocktail was added to permeabilized cells,
 
z
 
50% of VSV-G protein was processed to an endo-
H–resistant form (top band, lane 2), and this is set as
100% processing. The percent processing is analogous to
the level of processing reported previously (Tisdale and
Balch, 1996; Subramanian et al., 1996). In contrast, when
transport was analyzed with an ATP-depleting system,
VSV-G protein remained sensitive to endo-H (bottom
band, lane 1), and this is set as 0% processing. The addi-
tion of increasing amounts of affinity-purified anti–p115
antibodies (from 0.1 to 0.8 
 
m
 
g) led to a dose-dependent
inhibition of VSV-G protein processing to the endo-
H–resistant form (lanes 3–6). To provide quantitative
data on VSV-G processing, analogous data from repeated
experiments (
 
n
 
 5 
 
3) were evaluated by densitometry, and
the average of relative percent is presented in the accom-
panying bar graph. The relative processing was reduced
by 15% in the presence of 0.1 
 
m
 
g of antibody with 
 
.
 
80%
inhibition when 0.4 
 
m
 
g of anti–p115 antibodies were
Figure 3. Antibodies against
p115 block Golgi complex reas-
sembly during BFA wash-out.
WIF-B cells were treated with
BFA for 30 min, and then in-
jected with mAbs against p115
mixed with TR-dextran. Cells
were fixed after 10 min (A and
B), 30 min (C and D), or 120
min (E and F) of BFA wash-out,
and processed for immuno-
fluorescence using antibodies
against Mann II (A, C, and E).
Injected cells were identified by
their content of TR-dextran (B,
D, and F), and are traced in out-
line in A, C, and E. After 10 min
of BFA wash-out, Mann II relo-
cation to punctate structures is
indistinguishable in injected and
uninjected cells. After 30 and
120 min of BFA wash-out, Mann
II appears in morphologically
normal Golgi structures in unin-
jected cells, but remains in punc-
tate structures in injected cells. Arrowheads mark Golgi in injected cells, arrows point to Golgi in uninjected cells. Asterisk denotes a
more compact Golgi complex in injected cells. 
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added. When preimmune antibodies were added to the
transport assay, normal processing of VSV-G protein was
observed (data not shown).
To ensure that the inhibitory effects of the anti–p115 an-
tibodies were due to an interaction with p115, the anti-
bodies were preincubated either with GST-p115 fusion
protein or GST transferred to nitrocellulose strips. The
nonbound fractions were tested for inhibitory activity in
the semi-intact transport assay. As shown in Fig. 5 B, lane
3, preincubation of the antibody with GST-p115 nitrocel-
lulose strips efficiently neutralized its inhibitory effect on
traffic, and processing of VSV-G protein to the endo-
H–resistant form was comparable to the control situation
with complete cytosol (lane 2). In contrast, inhibition was
still apparent with antibodies incubated with GST strips
(lane 4), and processing of VSV-G protein to the endo-
H–resistant form was comparable to that in the absence of
ATP (lane 1). These results suggest that anti–p115 anti-
bodies block ER to Golgi transport through a specific in-
teraction with p115.
To extend these findings, VSV-G protein transport in
the presence of limiting amounts of p115 was analyzed. In
the semi-intact cell transport assay, exogenous rat liver
cytosol must be added to provide cytosolic and periph-
eral membrane proteins released during permeabilization
(Beckers et al., 1987). p115 is peripherally associated with
membranes, and during cell disruption, is largely released
 
into the cytosol (Waters et al., 1992; Nelson et al., 1998).
Rat liver cytosol contains high amounts of p115 (
 
z
 
0.5
 
m
 
g/mg). To examine if such exogenously added p115 is re-
quired for transport, p115 was removed from the cytosol
by immunodepletion. The extent of immunodepletion was
analyzed by immunoblotting (Fig. 5 C, p115 panel, lanes 2
and 3 compared with lane 4). The immunoblot was evalu-
ated by densitometry, and the relative amount of p115
present is shown in the accompanying bar graph. Up to
60% of cytosolic p115 was removed in lane 4. When such
p115-depleted cytosol was used in the transport assay,
VSV-G protein processing to the endo-H–resistant form
was inhibited by 
 
z
 
90%. Immunodepletion of cytosol with
nonspecific antibodies (affinity-purified rabbit anti–goat
IgG, lane 3) or preimmune serum (data not shown) had no
effect on VSV-G protein transport. Reactions containing
complete transport cocktail (lane 2) or cocktail containing
an ATP-depleting system (lane 1) were analyzed as posi-
tive and negative controls and defined as 100 and 0%
VSV-G protein processing, respectively.
To examine if addition of purified p115 could rescue
transport, p115-depleted cytosol (analogous to that in lane
4) was supplemented with increasing amounts of purified
p115. p115 was purified from rat liver cytosol on affinity-
purified anti–p115 antibodies cross-linked to a protein
A–Sepharose column. As shown in Fig. 5 D, the material
eluted from the anti–p115 IgG column (lane 1) contains a
Figure 4. p115 is associated with
VTCs moving cargo VSV-G pro-
tein from the ER to the Golgi.
NRK cells were infected with
VSVtsO45 at 428C for 3 h. The
cells were either fixed (A–C) or
incubated at 158C for 3 h (D–F)
or at 328C for 1 h (G–I) before
fixation. Cell were processed for
double label immunofluores-
cence using antibodies against
p115 (A, D, and G) and antibod-
ies against VSV-G protein (B, E,
and H). At 428C, VSV-G protein
is present in the ER (B),
whereas p115 is predominantly
localized to the Golgi (A). p115
and VSV-G protein colocalize in
peripheral VTCs after 158C in-
cubation (D–F), and in the Golgi
after 328C incubation (G–I). Bar
10 mm. 
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band of 
 
z
 
110 kD, whereas no such band was eluted from a
control preimmune IgG column (lane 2). To ensure that
the 110-kD band was p115, the 110-kD region was excised
from a gel, subjected to tryptic digestion and the peptides
were separated and characterized by MALDI mass spec-
trometry combined with sequence database searching. The
peptide mass map of 10 major peptides (Fig. 5 D) match
with p115, and no other rat protein in that molecular mass
range was found in the search. Analogous purified p115
was added to the p115 depleted cytosol. As shown in Fig. 5
C, p115 panel, lanes 5–7, and bar graph, the supplemented
cytosol contained 110, 
 
z
 
140, and 
 
z
 
160% of p115 in
untreated cytosol, respectively. When such supplemented
cytosols were used in the transport assay, VSV-G pro-
tein was processed to the endo-H–resistant form with
 
z
 
40, 
 
z
 
50, and 
 
z
 
100% processing efficiency, respectively
(VSV-G panel, lanes 5–7, and bar graph). Taken together,
these results indicate that p115 is essential for VSV-G pro-
tein delivery from the ER to the Golgi.
 
p115 Is Required for ER to Golgi Transport at a Step 
after the rab1 Requirement and before the
Ca
 
2
 
1
 
 Requirement
 
Previous work suggested that p115 functions to tether do-
nor and acceptor membranes before membrane fusion
(Barroso et al., 1995; Sönnischen et al., 1998), but did not
place the p115 requirement relative to requirements for
other known transport factors. Studies on Uso1p sug-
gested that its function is regulated by Ypt1p (Sapperstein
Figure 5. p115 is essential for
ER to Golgi transport. ER to
Golgi transport was performed
in semi-intact NRK cells. Trans-
port is measured as the percent-
age of VSV-G protein processed
from the endo-H–sensitive (S)
to the endo-H–resistant (R)
form. (A) Transport reactions
contained complete transport
cocktail (lanes 2–6), or cocktail
with ATP-depleting system
(lane 1). Reactions were supple-
mented with increasing amounts
of affinity-purified anti–p115 an-
tibodies (lanes 3–6). Transport
of VSV-G protein was propor-
tionally inhibited in the pres-
ence of antibodies against p115.
Analogous gels (n 5 3) were
quantitated by densitometry and
the averages are presented in
the bar graph. Transport in lane
1 is set as 0% and in lane 2 as
100%. (B) Transport reactions
contained complete transport
cocktail (lane 2), cocktail with
ATP-depleting system (lane 1),
or cocktail supplemented with
anti–p115 antibodies preincu-
bated with GST-p115 (lane 3),
or GST (lane 4). Preincubation
of anti–p115 antibodies with
GST-p115 neutralized their in-
hibitory effect on transport. (C)
Transport reactions contained
complete transport cocktail
(lanes 2–7), or cocktail with
ATP-depleting system (lane 1). In lane 3, transport cocktail contained cytosol preincubated with control IgGs. In lane 4, transport cock-
tail contained cytosol preincubated with anti–p115 antibodies. Reduced level of p115 is visible in lane 4 and leads to inhibition of VSV-G
protein transport. Increasing amounts of purified p115 were added to the cytosol shown in lane 4. Addition of purified p115 overcame
the inhibitory effect of p115 removal and supported VSV-G protein transport (lanes 5–7). Analogous gels (n 5 3) were quantitated by
densitometry, and the averages are presented in the bar graph. Transport in lane 1 is set as 0% and in lane 2 as 100%. An aliquot of each
transport reaction was probed by immunoblotting with anti–p115 antibodies and the immunoblot is shown in panel p115. The same
amount of p115 was used in lane 1 as in lane 2 and only reaction in lane 2 was analyzed. (D) Rat liver cytosol was incubated with anti–
p115 antibodies or control IgGs cross-linked to protein A–Sepharose. Bound material was eluted and analyzed by SDS-PAGE. An
z110-kD band was visible after Coomassie blue staining in material eluted from anti-p115 column (lane 1) but not in control eluate
(lane 2). The z110-kD band was excised, digested with trypsin, and the resulting peptides analyzed by MALDI mass spectrometry. The
peptide mass map of the 10 most abundant peptides (marked by asterisks) matched the sequence of p115. 
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et al., 1996; Cao et al., 1998), and Ypt1p and its mamma-
lian homologue rab1 are essential for ER to Golgi trans-
port (Plutner et al., 1990, 1991; Schwaninger et al., 1992b;
Ferro-Novick and Jahn, 1994; Nuoffer et al., 1994). To or-
der the sequence of rab1- and p115-requiring transport
steps in mammalian cells, staging experiments were per-
formed. In the first stage, p115-depleted cytosol was added
to the semi-intact cell transport assay, and the cells were
incubated at the permissive temperature for 60 min to al-
low VSV-G protein to accumulate in the p115-arrested
compartment. The cells were collected, and in the second
stage, incubated with either p115-depleted cytosol, com-
plete cytosol, rab1-depleted cytosol, or complete cytosol
supplemented with anti–rab1 antibodies. Rab1-depleted
cytosol contained 
 
,
 
5% of the rab1 found in untreated cy-
tosol (data not shown), and 3 
 
m
 
g of anti–rab antibodies
were used, an amount similar to that shown previously to
be inhibitory in the semi-intact cell transport assay (Plut-
 
ner et al., 1991). As shown in Fig. 6 A (gel and bar graph,
lane 1), when p115-depleted cytosol was used in both
stages of the transport assay, 
 
,
 
10% of VSV-G protein was
processed to the endo-H–resistant form. This represents
the background of the assay and is set as 0% relative pro-
cessing. When complete cytosol (lane 2) was added in the
second stage, 
 
z
 
35% of VSV-G protein was transported to
the Golgi and acquired endo-H resistance (set as 100%
relative processing), the same extent as when completed
cytosol was used in both stages (data not shown). Signifi-
cantly, when rab1-depleted cytosol (lane 3), or complete
cytosol containing anti–rab1 antibodies (lane 4) were used,
comparable 
 
z
 
90% level of relative processing was ob-
served, indicating that progression of VSV-G protein from
the p115–depletion blocked compartment to the Golgi
does not require rab1.
In agreement with previous results showing partial inhi-
bition after rab1 depletion (Peter et al., 1998), when stages
I and II were performed with rab1-depleted cytosol, VSV-G
transport was blocked by 
 
z
 
60% (lane 5). When complete
cytosol was added in the second stage (lane 6), VSV-G pro-
tein processing was 
 
.
 
80% of that in lane 2. In contrast,
when p115-depleted cytosol was added in the second stage
(lane 7), VSV-G protein processing was inhibited by
 
z
 
60%, the same extent as when rab1-depleted cytosol was
used in both stages (lane 5). This suggests that movement
of VSV-G protein from the rab1–depletion blocked com-
partment to the Golgi requires p115. Together, the data
indicate that rab1 is required before the p115-requiring
step of VSV-G protein transport.
Using the same ER to Golgi transport assay, it has been
shown that Ca
 
2
 
1
 
 is required at a last transport step before
membrane fusion (Beckers and Balch, 1989; Aridor et al.,
1995). To determine if addition of anti–p115 antibodies or
p115 depletion inhibits ER to Golgi transport at a stage
before or after the Ca
 
2
 
1
 
 
 
requirement, staging experiments
were performed. In the first stage, 10 mM EGTA was
added to the semi-intact cell transport assay, and the cells
were incubated at the permissive temperature for 60 min
to allow VSV-G protein to accumulate in the EGTA-
arrested compartment. The cells were collected, and in
the second stage, incubated with either cytosol containing 10
mM EGTA, complete cytosol, p115-depleted cytosol, or
complete cytosol supplemented with anti–p115 antibodies.
As shown in Fig. 6 B (gel and bar graph, lane 1), when
EGTA was added to both stages of the transport assay,
 
z
 
3% of VSV-G protein acquired endo-H resistance. This
represents the background of the assay and is set as 0%
relative transport. When complete cytosol (lane 2) was
added in the second stage, 
 
z
 
35% of VSV-G protein was
processed, and this represents 100% relative processing.
The 
 
z
 
35% processing is analogous to the percent process-
ing observed when complete cytosol is added to both
stages of transport (data not shown). Significantly, when
p115-depleted cytosol (lane 3), or complete cytosol con-
taining p115 antibodies (lane 4) was added in the second
stage, 
 
z
 
100% relative processing was observed, suggesting
that progression of VSV-G protein from the Ca
 
2
 
1
 
-arrested
compartment to the Golgi does not require p115.
This was confirmed by reverse staging. As shown in Fig.
6 B (lanes 5 and 6), addition of p115-depleted cytosol to
both stages of the transport assay resulted in 
 
z15% of
Figure 6. p115 acts after the rab1 requirement and before the
Ca21 requirement. Two-stage ER to Golgi transport was per-
formed in semi-intact NRK cells. In stage I, cells were incubated
for 60 min at 328C. Cells were then pelleted and resuspended in
fresh transport cocktail and incubated in stage II for 45 min at
328C. Transport is measured as the percentage of VSV-G protein
processed from the endo-H–sensitive (S) to the endo-H–resistant
(R) form. (A) VSV-G protein is minimally processed when p115-
depleted cytosol is used in both stages (lane 1), and this is set as
0% relative processing. VSV-G protein is processed when com-
plete cytosol (lane 2) is used, and this is set as 100% relative pro-
cessing. VSV-G protein is processed when rab1-depleted cytosol
(lane 3) or cytosol containing anti–rab1 antibodies (lane 4) is
added during the second stage. VSV-G protein is not processed
when rab1-depleted cytosol is used in both stages (lane 5), but is
processed when complete cytosol is used in the second stage
(lane 6). VSV-G protein is not processed when p115-depleted cy-
tosol is added during the second stage (lane 7). The staging indi-
cates that p115 acts after the rab1-requiring step of transport. (B)
VSV-G protein is minimally processed when EGTA is added to
both stages (lane 1), and this is set as 0% relative processing.
VSV-G protein is processed when complete transport cocktail is
used in both stages (lane 2), and this is set as 100% relative pro-
cessing. VSV-G protein is processed when p115-depleted cytosol
(lane 3) or anti–p115 antibodies (lane 4) are added during the
second stage. VSV-G protein is not processed when p115-
depleted cytosol is added to both stages (lanes 5 and 6) or when
EGTA is added to the second stage (lane 8), but is processed
when complete cytosol is added to the second stage (lane 7). The
staging indicates that p115 precedes the Ca21-requiring step of
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VSV-G protein acquiring endo-H resistance (z40% rela-
tive processing). (In these experiments, p115 depletion
was incomplete [data not shown] and accounts for the in-
complete inhibition of VSV-G protein transport.) When
complete cytosol was added in the second stage (lane 7),
z30% of VSV-G protein was processed (z90% relative
processing). When cytosol containing EGTA was added in
the second stage, z5% of the VSV-G protein was trans-
ported to the Golgi and acquired endo-H resistance
(z10% relative processing) (lane 8). This suggests that
movement of VSV-G protein from the p115–depletion
blocked compartment to the Golgi stack requires Ca21.
Together, the results indicate that p115 is required before
the Ca21-requiring stage of VSV-G protein transport.
Morphological examination of VSV-G protein localiza-
tion in the presence of EGTA suggests that Ca21 is re-
quired for VTC delivery to the Golgi stack (Aridor et al.,
1995). Our finding that p115 is required at a stage of trans-
port before the Ca21 requirement suggested that p115
might also be required at that stage.
p115 Is Required for a VTC Step before the Delivery of 
VSV-G Protein to the Golgi Stack
To define where anti–p115 antibodies and p115 depletion
blocked transport of VSV-G protein, morphological trans-
port assays were performed. Addition of anti–p115 anti-
bodies (z10 ng IgG/ml transport assay, an amount analo-
gous to that shown to inhibit the biochemical assay in Fig.
5 A, lane 5) to the morphological transport assay pre-
vented VSV-G protein from moving to the Golgi (Fig. 7,
A–C). A representative experiment (from .10 analyses) is
presented. VSV-G protein was not detected in the ER, in-
dicating that anti–p115 antibodies had no effect on VSV-G
protein exit from the ER and its delivery to post-ER trans-
port intermediates, but prevented delivery of such inter-
mediates to the Golgi. This resulted in accumulation of
VSV-G protein in peripheral VTCs, most of which were
labeled with anti–p115 antibodies (C, arrowheads). Anti–
p115 antibodies were also detected in the Golgi (C, ar-
rows), perhaps because of incomplete removal of p115
Figure 7. Antibodies against p115 block ER to
Golgi transport of VSV-G protein at a pre-Golgi
stage. NRK cells were infected with VSVtsO45
for 3 h at 428C. Cells were permeabilized and
supplemented with complete transport cocktail
supplemented either with anti–p115 antibodies
(A–C) or control antibodies (D–F). After trans-
port at 328C for 90 min, cells were processed by
double label immunofluorescence using anti-
p115 (A and D) and anti–VSV-G protein (B and
E) antibodies. Addition of anti–p115 antibodies
to the transport assay has no effect on VSV-G
protein exit from the ER, but prevents VSV-G
protein transport to the Golgi (A–C) and causes
accumulation of VSV-G protein in scattered
VTCs. Arrowheads point to peripheral struc-
tures containing VSV-G protein and anti–p115
antibodies. Arrows indicate Golgi elements la-
beled with anti–p115 antibodies but lacking
VSV-G protein. Addition of control antibodies
to the transport assay had no effect on VSV-G
protein transport, and VSV-G protein was effi-
ciently delivered to the Golgi (D–F). Bar 10 mm.The Journal of Cell Biology, Volume 147, 1999 1214
from membranes during permeabilization. Alternatively,
anti–p115 antibodies might act by trapping p115 on Golgi
membranes through the formation of inactive complexes.
Addition of equivalent amounts of preimmune antibodies
to the transport assay had no effect on VSV-G protein
transport, and VSV-G protein was efficiently delivered to
the Golgi, where it colocalized with p115 (D–F). The same
pattern was observed when monoclonal anti–Mann II anti-
bodies were added to the reaction (data not shown).
When p115-depleted cytosol (analogous to that unable
to support the biochemical assay in Fig. 5 C, lane 4) was
used in the morphological transport assay, VSV-G protein
was also not transported to the Golgi, as evidenced by its
lack of colocalization with Mann II (Fig. 8, A–C). Two
representative cells from two different experiments are
shown in these panels. VSV-G protein localized predomi-
nantly to peripheral VTCs, indistinguishable from those
seen in the presence of anti–p115 antibodies (compare to
Fig. 7 B). VSV-G protein was almost exclusively in periph-
eral VTCs, and was not present to any significant extent in
the ER, confirming that p115 is not involved in ER exit
and delivery of cargo to more distal transport intermedi-
ates. VSV-G protein was efficiently transported to the
Golgi when complete cytosol was used (Fig. 8, D–F).
Taken together, these results indicate that p115 function is
required after the formation of post-ER VTCs but before
their delivery to the Golgi stack. This defines a novel func-
tion for p115, and identifies the first step of membrane
transport in which p115 participates.
Differential Processing of Arrested VSV-G Protein
Since addition of anti–p115 antibodies or p115 depletion
inhibits VSV-G protein delivery to the Golgi and causes
its accumulation in peripheral VTCs, we expected that the
arrested VSV-G protein will not be processed by any of
the Golgi glycosyl-modifying enzymes. In agreement, our
data show that the arrested VSV-G protein remains endo-H
sensitive, indicating a lack of processing by NAGT-1 and
Mann II. To examine whether the arrested VSV-G pro-
tein is processed by the cis-Golgi enzyme Mann I, endo-D
resistance/sensitivity was analyzed in LEC-1 and NRK
cells.
Mutant LEC-1 cells that lack NAGT-1 were used first
because in these cells oligosaccharide modifications stop
after Mann I processing (Stanley et al., 1975). VSV-G pro-
tein is endo-D resistant while in the ER and becomes
endo-D sensitive after being transported and processed by
Mann I. When infected cells were permeabilized and used
in the semi-intact cell transport assay in the presence of an
Figure 8. p115 depletion blocks
ER to Golgi transport of VSV-G
protein at a pre-Golgi stage.
NRK cells were infected with
VSVtsO45 for 3 h at 428C. Cells
were permeabilized and supple-
mented with transport cocktails
containing p115-depleted cyto-
sol (A–C) or complete cytosol
(D–F). After transport at 328C
for 90 min, cells were processed
by double label immunofluores-
cence using anti–VSV-G pro-
tein (A and D) and anti–Mann II
(B and E) antibodies. Depletion
of p115 from the transport assay
had no effect on VSV-G protein
exit from the ER, but prevented
VSV-G protein transport to the
Golgi (A–C) and caused accu-
mulation of VSV-G protein in
peripheral VTCs lacking Mann
II. In the presence of complete
cytosol, VSV-G protein was effi-
ciently delivered to the Golgi
(D–F). Bar 10 mm.Alvarez et al. p115 Is Required for VTC Delivery to the Golgi Stack 1215
ATP-depleting system, VSV-G protein was endo-D resis-
tant (Fig. 9 A, 2ATP). When complete transport cocktail
was used, a proportion (z60%) of VSV-G protein became
endo-D sensitive, and this is taken as the standard to
which other reactions are compared (Fig. 9 A, 1ATP).
Unexpectedly, VSV-G protein was processed to the endo-
D–sensitive form when anti–p115 antibodies were added
to the transport assay (Fig. 9 A, anti-p115) in an amount
analogous to that found to block acquisition of endo-H re-
sistance in NRK cells (Fig. 5 A, lane 6). Addition of con-
trol antibodies had no effect on VSV-G protein processing
(Fig. 9 A, control). Similarly, when p115-depleted cytosol
was used in the transport assay, VSV-G protein was pro-
cessed to the endo-D–sensitive form (Fig. 9 B, gel and bar
graph, lanes 5 and 6). Even a significant depletion of p115
(.80% of p115 was depleted in lanes 5 and 6 as compared
with lane 2) had no effect on the amount of VSV-G pro-
tein sensitive to endo-D. The level of p115 (z20% of con-
trol) that supported the processing to the endo-D–sensi-
tive form in LEC-1 cells was unable to support processing
to the endo-H–resistant form in NRK cells (compare Fig. 9
B, lane 6, to Fig. 5 C, lane 4). The level of endo-D process-
ing in reactions containing cytosol immunodepleted with
anti–p115 antibodies was similar to that when control (Fig.
9 B, lane 3) or preimmune (Fig. 9 B, lane 4) antibodies
were used for immunodepletion.
To test VSV-G protein processing by Mann I while in
pre-Golgi transport intermediates, we arrested VSV-G
protein transport by incubating the LEC-1 cells at 158C
(Rowe et al., 1998). As shown in Fig. 9 C, VSV-G protein
is resistant to endo-D when cells are incubated at 428C
(lanes 1 and 4) and becomes endo-D sensitive when incu-
bated at 328C (lanes 2 and 5). When cells were incubated
at 158C, z70% of VSV-G protein was endo-D sensitive
(lanes 3 and 6), suggesting that the VSV-G protein was
processed by Mann I.
Analogous experiments were performed in NRK cells,
but both endo-H and endo-D resistance/sensitivity of
VSV-G protein arrested by various treatments were
tested. These digestions were done in parallel since only
endo-D sensitivity of an endo-H–sensitive form of VSV-G
will define whether VSV-G protein is processed by Mann I
Figure 9. VSV-G protein is differentially endo-D resistant/sensi-
tive in LEC-1 and NRK cells. (A and B) ER to Golgi transport
was performed in semi-intact LEC-1 cells. After transport, the
sensitivity/resistance of VSV-G protein to endo-D was analyzed.
(A) VSV-G protein is endo-D resistant when transport cocktail
lacking ATP is used (2ATP), and this is set as 0% relative pro-
cessing. A proportion of VSV-G protein is endo-D sensitive
when complete transport cocktail is used (1ATP), and this is set
as 100% relative processing. A similar proportion of VSV-G pro-
tein is endo-D sensitive when complete transport cocktails con-
taining control antibodies (control) or anti–p115 antibodies (anti-
p115) are used. (B) VSV-G protein is endo-D resistant when
transport cocktail lacking ATP is used (lane 1), and this is set as
0% relative processing. A proportion of VSV-G protein is endo-D
sensitive when complete transport cocktail is used (lane 2), and
this is set as 100% relative processing. A similar proportion of
VSV-G protein is endo-D sensitive when complete transport
cocktails containing cytosol immunodepleted with control anti-
bodies (lane 3), preimmune antibodies (lane 4), or anti–p115 an-
tibodies (lanes 5 and 6) are used. Analogous gels (n 5 3) were
quantitated by densitometry and averages are presented as a bar
graph. An aliquot of each transport reaction was probed by im-
munoblotting with anti–p115 antibodies and the immunoblot is
shown in panel p115. The relative amounts of p115 in each trans-
port reaction are presented in the bar graph. The amount of p115
in lane 1 is set as 100%. (C) LEC-1 cells were infected with
VSVtsO45 for 3 h at 428C, and either analyzed directly or incu-
bated at 328C for additional 1 h or at 158C for additional 3 h be-
fore analysis. Cells were collected and analyzed directly or after
endo-D digestion. Processing of VSV-G protein from the endo-
D–resistant (R) to the endo-D–sensitive (S) form is shown. A sin-
gle VSV-G band is seen in untreated samples regardless of incu-
bation temperature (lanes 4–6). VSV-G is resistant to endo-D
when retained in the ER during the 428C incubation (lane 1), but
becomes endo-D sensitive when transported to the Golgi during
a 328C incubation (lane 2) or when arrested in peripheral VTCs
during a 158C incubation (lane 3). (D, lanes 1–3 and 5–7) ER to
Golgi transport was performed in semi-intact NRK cells. After
transport, the sensitivity/resistance of VSV-G protein to endo-H
and endo-D was analyzed in parallel. VSV-G protein is endo-H
sensitive (lane 1) and endo-D resistant (lane 5) when transport
cocktail lacking ATP is used. VSV-G protein is endo-H resistant
(lane 2) and endo-D resistant (lane 6) when complete transport
cocktail is used. VSV-G protein is endo-H sensitive (lane 3) and
endo-D resistant (lane 7) when complete transport cocktails con-
taining anti–p115 antibodies are used. (D, lanes 4 and 8) NRK
cells were infected with VSVtsO45 (3 h at 328C), pulsed-labeled
at the restrictive temperature (10 min at 428C) and chased in
complete medium for 3 h at 158C. Cells were collected and di-
gested with either endo-H (lane 4) or endo-D (lane 8). VSV-G
protein is endo-H sensitive and endo-D resistant when arrested
in peripheral VTCs at 158C.The Journal of Cell Biology, Volume 147, 1999 1216
but not NAGT-1 and Mann II. As shown in Fig. 9 D, when
transport was performed in the presence of an ATP-
depleted transport cocktail, VSV-G protein is endo-H
sensitive (lane 1) and endo-D resistant (lane 5). When
transport was performed in the presence of a complete
transport cocktail, VSV-G becomes endo-H resistant (lane
2) and is endo-D resistant (lane 6). When affinity-purified
anti–p115 antibodies were added to the complete trans-
port assay, VSV-G protein is endo-H sensitive (lane 3) and
endo-D resistant (lane 7). These results differ from the re-
sults of analogous experiments performed in LEC-1 cells
(Fig. 9 A), in which addition of affinity-purified anti–p115
antibodies leads to VSV-G protein that is endo-D sensi-
tive.
In an attempt to clarify this difference, we analyzed the
endo-H and endo-D sensitivity of VSV-G protein ar-
rested in peripheral VTCs when NRK cells are incubated
at 158C. As shown in Fig. 9 D, lanes 4 and 8, VSV-G pro-
tein was endo-H sensitive and endo-D resistant. This
result differs from that in LEC-1 cells, where an endo-
D–sensitive form was observed after 158C incubation.
Together, the data show that endo-D–sensitive VSV-G
protein is seen in LEC-1 cells in the presence of anti–p115
antibodies or when cells are incubated at 158C, whereas
the same treatments of NRK cells result in a VSV-G pro-
tein that is endo-D resistant. A likely explanation for this
difference is that the lack of p115 requirement in LEC-1
cells is due to incomplete inactivation/removal of endoge-
nous p115 from those cells as opposed to NRK cells. Al-
ternatively, since we observe a difference in VSV-G protein
endo-D sensitivity in intact LEC-1 and NRK incubated at
158C, oligosaccharide processing of VSV-G protein might
be different in the two cell lines. Currently, we have no
explanation for the different results in LEC-1 and NRK
cells, and cannot define whether p115 is required for
transport of VSV-G protein into a Mann I–containing
compartment.
Mann I Redistributes from the Golgi When ER to Golgi 
Transport Is Blocked by 158C Incubation or
p115 Depletion
The differences in the biochemical results in LEC-1 and
NRK cells prompted us to examine Mann I localization
in traffic-arrested NRK cells since all previous morpholog-
ical analyses (Figs. 4, 7, and 8) have been done in NRK cells.
Previous EM immunoperoxidase studies indicated that in
NRK cells, Mann II is localized in the medial-cisternae,
whereas Mann I is localized in the trans-cisternae and the
TGN, and at the light immunofluorescence level, both
Mann II and Mann I are concentrated in the Golgi region
(Velasco et al., 1993). In agreement, Mann I and II colo-
calized in the Golgi region in cells incubated at 378C,
although Mann I was also present in a more diffuse
non-Golgi pattern (Fig. 10, A–C). Significantly, Mann I
redistributed from the Golgi to peripheral punctate struc-
tures when cells were incubated at 158C, whereas Mann II
did not show such redistribution (Fig. 10, D–F). To charac-
terize these pre-Golgi elements, VSVtsO45-infected cells
were shifted from 40 to 158C for 3 h, and then processed to
localize Mann I and VSV-G protein. As shown in Fig. 10,
G–I, Mann I redistributed from the Golgi to peripheral
structures, some of which (arrowheads, I) contained VSV-G
protein. In contrast, Mann II did not show redistribution
(Fig. 10, J–L).
To determine whether Mann I can redistribute to pre-
Golgi VTCs arrested by p115 depletion, semi-intact cells
incubated with transport assays supplemented with com-
plete cytosol or with p115-depleted cytosol were processed
for double label immunofluorescence to localize VSV-G
protein and Mann I. As shown in Fig. 10, M–O, when
transport was performed with complete cytosol, Mann I
was detected in a typical perinuclear Golgi structure,
where it colocalized with VSV-G protein. In contrast,
when transport was performed with p115-depleted cytosol,
Mann I was found colocalizing with peripheral VTCs (Fig.
10, P–R, arrowheads in R point to a VTC-containing VSV-G
protein and Mann I). As already shown in Fig. 8, Mann II
did not show such relocation. Together, these results indi-
cate that Mann I can cycle to pre-Golgi compartments
during cargo transit from the ER to the Golgi. Further-
more, our data show that p115 is not required for events
before and including the recycling of Mann I from the
Golgi to peripheral compartments, but is essential for the
subsequent events leading to delivery of cargo and Mann I
to the Golgi.
Discussion
Requirement for p115 in Maintaining Golgi Structure
Functional p115 appears to be required for normal Golgi
morphology in intact cells since injection of anti–p115 an-
tibodies into WIF-B cells resulted in the appearance of
Golgi fragments scattered throughout the injected cells.
This antibody effect appears specific since microinjec-
tion of anti–59-nucleotidase antibodies does not lead to
changes in Golgi morphology. Normal Golgi architecture
varies in different cells, but seems to be dependent on
the balance of incoming and outgoing membrane traffic
through the structure. Perturbation of the anterograde or
retrograde traffic by various treatments of cells leads to
Golgi disruption. Specifically, changes in Golgi morphol-
ogy were observed in cells overexpressing ADP-ribosyla-
tion factor (Dascher and Balch, 1994), injected with rab1a
mutant (Wilson et al., 1994), or anti–b-COP antibodies
(Pepperkok et al., 1993). Similarly, treatment of cells with
BFA (Misumi et al., 1986; Fujiwara et al., 1988; Lippin-
cott-Schwartz et al., 1989), nocodazole (Storrie and Yang,
1998), or okadaic acid (Pryde et al., 1998) has a dramatic
effect on Golgi integrity. The exact mechanism of the dis-
ruptive action of anti–p115 antibodies on Golgi structure
is currently unknown, but it is possible that the antibodies
perturb transport pathways between the ER and the
Golgi. Specifically, the antibodies could inhibit p115 activ-
ity in vivo by blocking p115 interactions with GM130 (Na-
kamura et al., 1997; Nelson et al., 1998), giantin (Sönnis-
chen et al., 1998), or another, as yet unidentified, protein.
Alternatively, anti–p115 antibodies might act by trapping
p115 on the membranes through the formation of inactive
complexes.
Presence of anti–p115 antibodies in cells did not prevent
the redistribution of Mann II to the ER after BFA treat-
ment, but the anti–p115 antibodies prevented the reassem-Alvarez et al. p115 Is Required for VTC Delivery to the Golgi Stack 1217
bly of Golgi complexes during subsequent BFA wash-out.
The requirement for functional p115 manifested late, after
exit of Golgi enzymes from the ER and delivery to periph-
erally scattered punctate structures. Significantly, these
structures did not move towards the MTOC and did not
coalesce into a centrally located Golgi complex. The effect
of anti–p115 antibodies was similar to that of anti–EAGE
(anti–b-COP) antibodies, which also interfere with the
proper reassembly of compact Golgi complexes in a juxta-
nuclear region during a BFA wash-out (Scheel et al.,
1997). Although our findings place the functional require-
ment for p115 in ER to Golgi traffic between the VTCs
and the Golgi, it remains to be determined which step of
the anterograde or retrograde transport is blocked by
anti–p115 antibodies in vivo.
Requirement for p115 in ER to Golgi Transport
The previous finding that p115 is abundant on VTCs (Nel-
son et al., 1998) was extended in this study to show that
Figure 10. Mann I relocates
from the Golgi to arrested pre-
Golgi VTCs. NRK cells grown
at 378C (A–C) or incubated for
3 h at 158C (D–F) were processed
for double label immunofluores-
cence using anti–Mann I (A and
D) and anti–Mann II (B and E)
antibodies. In cells grown at
378C, Mann I colocalized with
Mann II in the Golgi region (C),
but after 158C incubation, Mann
I relocated to peripheral punc-
tate structures and did not colo-
calize with the Golgi localized
Mann II (F). NRK cells infected
with VSVtsO45 were incubated
for 2 h at 428C and for an addi-
tional 3 h at 158C (G–L). Cells
were processed for double label
immunofluorescence using anti–
Mann I (G) and anti–VSV-G
protein (I) antibodies, or anti–
Mann II (J) and anti–VSV-G
protein antibodies (K). Mann I
is present in dispersed punctate
structures, some of which con-
tain VSV-G protein (I, arrow-
heads). Mann II remains within
the Golgi and does not relocate
to peripheral structures contain-
ing VSV-G protein (L). NRK
cells infected with VSVtsO45
were incubated for 3 h at 428C,
permeabilized, and supple-
mented with transport cocktails
containing complete cytosol
(M–O) or p115-depleted cyto-
sol (P–R). After transport at
328C for 90 min, cells were pro-
cessed for double label immuno-
fluorescence using anti–Mann I
(M and P) and anti–VSV-G pro-
tein (N and Q) antibodies. In re-
actions containing complete
cytosol, VSV-G protein is deliv-
ered to the Golgi where it colo-
calizes with Mann I (O). In reac-
tions containing p115-depleted
cytosol, Mann I relocates to pre-
Golgi VTCs containing arrested
VSV-G protein (R, arrow-
heads). Bar, 10 mm.The Journal of Cell Biology, Volume 147, 1999 1218
p115-containing VTCs are functional and carry cargo
VSV-G protein from the ER to the Golgi. The possible in-
volvement of p115 in this part of the secretory pathway
was examined using previously established ER to Golgi
transport assays that measure biochemically or morpho-
logically the movement of VSV-G protein from the ER to
the Golgi in semi-intact cells. Our biochemical results
show that anti–p115 antibodies or p115 depletion specifi-
cally block VSV-G protein transport before acquisition of
endo-H resistance, believed to represent the delivery of
VSV-G protein to the cis/medial-cisternae of the Golgi
stack. Unexpectedly, morphological examination showed
that in the presence of anti–p115 antibodies or p115 deple-
tion, VSV-G protein was not delivered to the Golgi stack,
but instead was arrested in pre-Golgi peripheral VTCs.
These findings indicate that p115 is not required for VSV-G
proteins to efficiently exit the ER and be delivered to mor-
phologically normal peripheral VTCs, but is essential for
the subsequent delivery of such VTCs to the Golgi stack.
What is the role of p115 in ER to Golgi traffic? Because
p115 is predominantly associated with VTCs and p115 de-
pletion arrests transport in VTCs, we favor the hypothesis
that p115 functions while on VTCs. A possible role for
p115 could be to mediate delivery of essential components
from the Golgi to VTCs, by tethering Golgi-derived recy-
cling vesicles to VTCs before fusion. This hypothesis is
suggested by the finding that a subpopulation of Golgi-
derived COP I vesicles (albeit produced under the non-
physiological conditions of GTPgS treatment) is enriched
in giantin, a protein known to bind p115 (Sönnischen et
al., 1998). Giantin is an extended coiled-coil transmem-
brane protein and the interaction between p115 on VTCs
and giantin on COP I vesicles could theoretically span the
distance of .400 nm, raising the possibility that p115 on
VTCs might act to catch and tether giantin-containing
Golgi-derived COP I vesicles. Fusion of such vesicles
would deliver components essential for VTC maturation
and subsequent delivery to the Golgi stack.
Alternatively, p115 might function to mediate VTC mo-
tility on microtubules. This is suggested by the fact that the
p115-induced block in ER to Golgi traffic is biochemically
and morphologically similar to that caused by 158C in-
cubation, when dynein/dynactin–mediated movement of
VTCs on microtubules is inhibited (Presley et al., 1997).
Furthermore, VSV-G protein is arrested in peripheral
VTCs in cells overexpressing the dynamitin subunit of the
dynactin complex (Presley et al., 1997), and their pattern is
indistinguishable from VTCs arrested by anti–p115 anti-
body addition or p115 depletion. Overexpression of dyna-
mitin disrupts the dynactin complex, separating the Arp-1
filament from the dynein-binding arm of p150Glued (Eche-
verri et al., 1996; Burkhardt et al., 1997) and prevents mi-
crotubule-mediated motility. Interestingly, a link between
microtubule movement and rab proteins has been estab-
lished by the finding that the Golgi-localized rab6 interacts
with rabkinesin, a Golgi-associated kinesin-like motor
protein that binds to microtubules and is likely to mediate
membrane movement along microtubules (Echard et al.,
1998). Whether rab1 might also have motor proteins (per-
haps of the dynein/dynactin family) as one of its effectors
remains to be determined. However, it is interesting that
p115 structure is similar to that of kinesin (a dimer with
globular heads, a central coiled-coil tail, and a tail do-
main), although p115 does not contain an ATP-binding/
hydrolysis domain and does not interact with microtubules
(data not shown).
It is equally possible that p115 is required to recruit or
activate other uncharacterized factors that will ultimately
allow VTC transport and fusion. We do not consider it
likely that p115 function in VTC dynamics involves inter-
action with GM130, since GM130 is not detected on VTCs
(Nelson et al., 1998) or Golgi-derived COP I vesicles (Sön-
nischen et al., 1998), and appears restricted to the Golgi
stack. It is more probable that p115–GM130 interactions
occur after the VTCs are delivered to the Golgi stack.
Functional p115 was shown to be required in ER to
Golgi traffic after the rab1-dependent step of transport.
Rab1 has been shown previously to be required after COP
II vesicle budding and after the assembly of peripheral
VTCs (Peter et al., 1998). In semi-intact cells supple-
mented with the rab1a (N124I) mutant that is defective for
guanine nucleotide binding, VSV-G protein has been
shown at the ultrastructural level to accumulate in tubular
structures with associated coated vesicular profiles (Pind
et al., 1994), but the morphology of the p115-arrested
transport intermediates remains to be analyzed. The be-
havior of p115 and rab1 in mammalian cells is analogous
to that of Uso1p and Ypt1 in yeast, since Ypt1p appears to
act upstream of Uso1p, and might be indirectly involved in
recruiting Uso1p to the membranes (Cao et al., 1998).
Whether rab1 performs a similar function for p115 is un-
certain since significant differences in the dynamics of
transport intermediates (e.g., yeast do not appear to have
extensive VTCs) are evident.
p115 was found to act before the Ca21-requiring step,
which is considered to be the last stage of transport before
fusion (Aridor et al., 1995). SNARE pairing precedes
Ca21 requirement (Chen et al., 1999), and our data are
consistent with the reported requirement for Uso1p be-
fore SNARE complex formation (Sapperstein et al., 1996;
Barlowe, 1997; Cao et al., 1998).
Cycling of Golgi Enzymes to Pre-Golgi Compartments
This report documents the first instance of a morphologi-
cally observed relocation of Mann I from the Golgi stack
to peripheral pre-Golgi structures. The relocation is ap-
parent in cells in which ER to Golgi transport is blocked
by 158C incubation or p115 depletion, suggesting that
Mann I (like other Golgi proteins) cycles between the
Golgi and the ER. The mechanism of Golgi protein recy-
cling is largely undefined. Recycling might occur directly
from the Golgi to the ER, since direct delivery via tubular
structures is observed during BFA-induced relocation of
Golgi proteins, and at least one Golgi glycosylating en-
zyme, GalT, can be detected in similar tubules under
physiological conditions (Sciaky et al., 1997). The BFA-
induced tubular relocation of Golgi proteins is COP I–inde-
pendent (Donaldson et al., 1991). Alternatively, recycling
might occur from the Golgi to VTCs. This pathway would
be consistent with the biochemical data showing that
VSV-G protein arrested in pre-Golgi transport intermedi-
ates can be processed by NAGT-1, which recycles via
small vesicles from the Golgi to the pre-Golgi intermedi-Alvarez et al. p115 Is Required for VTC Delivery to the Golgi Stack 1219
ates (Love et al., 1998). The recent results showing that
NAGT-1 binds coatomer in vitro (Dominguez et al., 1998),
and NAGT-1, as well Mann II and Gal-T, bud from the
Golgi in COP I–coated vesicles (Lanoix et al., 1999) sug-
gest that COP I–coated vesicles might transport Golgi-
derived glycosyl transferases to pre-Golgi transport inter-
mediates. Based on the structural similarity of Mann I to
other glycosyltransferases (a type II transmembrane pro-
tein), it is possible that it also recycles via Golgi-derived
COP I–coated vesicles.
Previous work has defined the kinetics with which Golgi
resident proteins cycle between the Golgi and the ER.
Several Golgi proteins such as KDEL-R, TGN38 (Cole et al.,
1998), and gp27 (Fullekrug et al., 1999), and glycosylat-
ing enzymes such as N-acetylgalactosaminyltransferase-2
(GalNAc-T2) and GalT (Storrie et al., 1998) have been
shown to cycle with half lives between 20 min (e.g., the
KDEL-R; Cole et al., 1998) and 2–3 h (e.g., gp27 [Fulle-
krug et al., 1999]; GalNAc-T2 and GalT [Storrie et al.,
1998]). Based on our observation that the majority of
Mann I relocates from the Golgi and appears in blocked
VTCs during a 90-min incubation at 378C (the time course
of the semi-intact transport assay), it appears that Mann I
cycles with relatively fast kinetics. Although the semi-
intact cell system used in our studies is not designed to an-
alyze recycling pathways, the results showing relocation of
Mann I, but not of Mann II to peripheral VTCs suggests
that Mann II cycles with significantly slower kinetics.
The recycling kinetics of Mann I seem more similar to
those of the ERGIC proteins, KDEL-R and ERGIC53,
which cycle rapidly at 378C. These proteins also relocate to
peripheral VTCs during longer (usually z3 h) incubations
at 158C. However, Mann I does not appear to be a
bonafide component of the ERGIC since EM analysis
showed it to be localized throughout the Golgi stack, with
highest concentration in the trans-cisternae and the TGN,
rather than the cis-face of the stack (Velasco et al., 1993).
This suggests that rapid cycling is not restricted to resi-
dents of the ERGIC, and that proteins with steady state
distribution in more distal Golgi compartments including
the TGN, also contain signals for rapid cycling. Whether
the recycling mechanisms are the same and involve COP I
vesicles, or are distinct remains to be elucidated.
Our morphological results have direct bearing on the con-
troversy regarding the mode of cargo transport through
the Golgi. The finding that Mann I efficiently relocates
from the Golgi stack to colocalize with peripheral cargo-
containing VTCs is less consistent with the anterograde
vesicular traffic model than with the maturation model for
exocytic traffic. Our results are not consistent with the an-
terograde vesicular traffic model, in which glycosyl-trans-
ferases remain relatively stationary in distinct Golgi cister-
nae while the cargo is shuttled from proximal to distal
cisterna in small vesicles. The observed relocation sup-
ports the maturation model, in which cargo progresses
through the secretory pathway in a compartment that is
remodeled by the sequential recycling of processing en-
zymes from later Golgi compartments.
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